Who is sponsoring NCT04398147?

NCT04398147 is sponsored by CanSino Biologics Inc..

What drugs are being tested in NCT04398147?

Interventions in NCT04398147: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo.

Is NCT04398147 still recruiting?

NCT04398147 is currently status unknown. Last updated 2 July 2020.

Last reviewed 2020-07-02 · How we verify

NCT04398147

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

Status unknown Phase 1, PHASE2 Last updated 2 July 2020

What this trial tests

Phase 1, PHASE2 trial testing Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in COVID-19 in 696 participants. Status unknown.

Timeline

1 August 2020

Primary endpoint
20 December 2021

30 December 2021

Quick facts

Lead sponsor	CanSino Biologics Inc.
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	696
Start date	1 August 2020
Primary completion	20 December 2021
Estimated completion	30 December 2021
Sites	1 location across Canada

Drugs / interventions tested

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

CanSino Biologics Inc. — full company profile →

Who can join

Adults 18 to 84, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a phase I /II adaptive clinical trial to evaluate the safety, tolerability and the Immunogenicity of Ad5-nCoV in healthy adults from 18 to \<55 and 65 to \<85 years of age，with the randomized, observer-blind, dose-escalation design

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.
Weiss C, Carriere M, Fusco L, Capua I, et al · · 2020 · cited 303× · PMID 32519842 · DOI 10.1021/acsnano.0c03697
COVID-19 vaccines: rapid development, implications, challenges and future prospects.
Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. · · 2021 · cited 240× · PMID 33677814 · DOI 10.1007/s13577-021-00512-4
Efficacy and safety of COVID-19 vaccines.
Graña C, Ghosn L, Evrenoglou T, Jarde A, et al · · 2022 · cited 227× · PMID 36473651 · DOI 10.1002/14651858.cd015477
The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF, Zhang Y, Foged C, Thakur A. · · 2020 · cited 164× · PMID 32793245 · DOI 10.3389/fimmu.2020.01817
T-cell responses and therapies against SARS-CoV-2 infection.
Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, et al · · 2021 · cited 158× · PMID 32935333 · DOI 10.1111/imm.13262
Vaccines for COVID-19.
Tregoning JS, Brown ES, Cheeseman HM, Flight KE, et al · · 2020 · cited 154× · PMID 32935331 · DOI 10.1111/cei.13517
COVID-19: Coronavirus Vaccine Development Updates.
Zhao J, Zhao S, Ou J, Zhang J, et al · · 2020 · cited 136× · PMID 33424848 · DOI 10.3389/fimmu.2020.602256
A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic.
Funk CD, Laferrière C, Ardakani A. · · 2020 · cited 123× · PMID 32636754 · DOI 10.3389/fphar.2020.00937

Verify or expand the search:

Other trials of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Trials testing the same drug.

NCT05169008 — A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adoles · Phase 3 · terminated
NCT04840992 — Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation · Phase 1, PHASE2 · completed
NCT04566770 — A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) · Phase 2 · completed
NCT04526990 — Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above · Phase 3 · completed
NCT04540419 — Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 · Phase 3 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other CanSino Biologics Inc. trials

Trials by the same sponsor.

NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
NCT06708286 — A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) · Phase 2, PHASE3 · active not recruiting
NCT06700148 — A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds · Phase 3 · active not recruiting
NCT06120751 — A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population · Phase 3 · completed
NCT06101173 — A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Health · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04398147 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CanSino Biologics Inc.
Last refreshed: 2 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04398147.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing